[B]	O
IL-2	DNA
gene	DNA
[E]	O
expression	O
and	O
NF-kappa	O
B	O
activation	O
through	O
CD28	O
requires	O
reactive	O
oxygen	O
production	O
by	O
5-lipoxygenase	O
.	O

[B]	O
IL-2	NEG
gene	NEG
expression	NEG
and	NEG
NF-kappa	NEG
B	NEG
[E]	O
activation	O
through	O
CD28	O
requires	O
reactive	O
oxygen	O
production	O
by	O
5-lipoxygenase	O
.	O

[B]	O
IL-2	NEG
gene	NEG
expression	NEG
and	NEG
NF-kappa	NEG
B	NEG
activation	NEG
through	NEG
CD28	NEG
[E]	O
requires	O
reactive	O
oxygen	O
production	O
by	O
5-lipoxygenase	O
.	O

[B]	O
IL-2	NEG
gene	NEG
expression	NEG
and	NEG
NF-kappa	NEG
B	NEG
activation	NEG
through	NEG
CD28	NEG
requires	NEG
reactive	NEG
oxygen	NEG
production	NEG
by	NEG
5-lipoxygenase	NEG
[E]	O
.	O

IL-2	O
gene	O
expression	O
and	O
[B]	O
NF-kappa	protein
B	protein
[E]	O
activation	O
through	O
CD28	O
requires	O
reactive	O
oxygen	O
production	O
by	O
5-lipoxygenase	O
.	O

IL-2	O
gene	O
expression	O
and	O
[B]	O
NF-kappa	NEG
B	NEG
activation	NEG
through	NEG
CD28	NEG
[E]	O
requires	O
reactive	O
oxygen	O
production	O
by	O
5-lipoxygenase	O
.	O

IL-2	O
gene	O
expression	O
and	O
[B]	O
NF-kappa	NEG
B	NEG
activation	NEG
through	NEG
CD28	NEG
requires	NEG
reactive	NEG
oxygen	NEG
production	NEG
by	NEG
5-lipoxygenase	NEG
[E]	O
.	O

IL-2	O
gene	O
expression	O
and	O
NF-kappa	O
B	O
activation	O
through	O
[B]	O
CD28	protein
[E]	O
requires	O
reactive	O
oxygen	O
production	O
by	O
5-lipoxygenase	O
.	O

IL-2	O
gene	O
expression	O
and	O
NF-kappa	O
B	O
activation	O
through	O
[B]	O
CD28	NEG
requires	NEG
reactive	NEG
oxygen	NEG
production	NEG
by	NEG
5-lipoxygenase	NEG
[E]	O
.	O

IL-2	O
gene	O
expression	O
and	O
NF-kappa	O
B	O
activation	O
through	O
CD28	O
requires	O
reactive	O
oxygen	O
production	O
by	O
[B]	O
5-lipoxygenase	protein
[E]	O
.	O

[B]	O
IL-2	NEG
[E]	O
gene	O
expression	O
and	O
NF-kappa	O
B	O
activation	O
through	O
CD28	O
requires	O
reactive	O
oxygen	O
production	O
by	O
5-lipoxygenase	O
.	O

[B]	O
IL-2	NEG
gene	NEG
expression	NEG
[E]	O
and	O
NF-kappa	O
B	O
activation	O
through	O
CD28	O
requires	O
reactive	O
oxygen	O
production	O
by	O
5-lipoxygenase	O
.	O

IL-2	O
[B]	O
gene	NEG
[E]	O
expression	O
and	O
NF-kappa	O
B	O
activation	O
through	O
CD28	O
requires	O
reactive	O
oxygen	O
production	O
by	O
5-lipoxygenase	O
.	O

IL-2	O
gene	O
expression	O
and	O
[B]	O
NF-kappa	NEG
[E]	O
B	O
activation	O
through	O
CD28	O
requires	O
reactive	O
oxygen	O
production	O
by	O
5-lipoxygenase	O
.	O

IL-2	O
gene	O
expression	O
and	O
[B]	O
NF-kappa	NEG
B	NEG
activation	NEG
[E]	O
through	O
CD28	O
requires	O
reactive	O
oxygen	O
production	O
by	O
5-lipoxygenase	O
.	O

IL-2	O
gene	O
expression	O
[B]	O
and	NEG
NF-kappa	NEG
B	NEG
[E]	O
activation	O
through	O
CD28	O
requires	O
reactive	O
oxygen	O
production	O
by	O
5-lipoxygenase	O
.	O

IL-2	O
gene	O
expression	O
and	O
NF-kappa	O
[B]	O
B	NEG
[E]	O
activation	O
through	O
CD28	O
requires	O
reactive	O
oxygen	O
production	O
by	O
5-lipoxygenase	O
.	O

IL-2	O
gene	O
expression	O
and	O
NF-kappa	O
B	O
activation	O
through	O
[B]	O
CD28	NEG
requires	NEG
[E]	O
reactive	O
oxygen	O
production	O
by	O
5-lipoxygenase	O
.	O

IL-2	O
gene	O
expression	O
and	O
NF-kappa	O
B	O
activation	O
through	O
[B]	O
CD28	NEG
requires	NEG
reactive	NEG
[E]	O
oxygen	O
production	O
by	O
5-lipoxygenase	O
.	O

IL-2	O
gene	O
expression	O
and	O
NF-kappa	O
B	O
[B]	O
activation	NEG
through	NEG
CD28	NEG
[E]	O
requires	O
reactive	O
oxygen	O
production	O
by	O
5-lipoxygenase	O
.	O

IL-2	O
gene	O
expression	O
and	O
NF-kappa	O
B	O
activation	O
[B]	O
through	NEG
CD28	NEG
[E]	O
requires	O
reactive	O
oxygen	O
production	O
by	O
5-lipoxygenase	O
.	O

IL-2	O
gene	O
expression	O
and	O
NF-kappa	O
B	O
activation	O
through	O
CD28	O
requires	O
reactive	O
oxygen	O
production	O
by	O
[B]	O
5-lipoxygenase	NEG
.	NEG
[E]	O

IL-2	O
gene	O
expression	O
and	O
NF-kappa	O
B	O
activation	O
through	O
CD28	O
requires	O
reactive	O
oxygen	O
[B]	O
production	NEG
by	NEG
5-lipoxygenase	NEG
[E]	O
.	O

IL-2	O
gene	O
expression	O
and	O
NF-kappa	O
B	O
activation	O
through	O
CD28	O
requires	O
reactive	O
oxygen	O
production	O
[B]	O
by	NEG
5-lipoxygenase	NEG
[E]	O
.	O

Our	O
data	O
suggest	O
that	O
[B]	O
lipoxygenase	protein
[E]	O
metabolites	O
activate	O
ROI	O
formation	O
which	O
then	O
induce	O
IL-2	O
expression	O
via	O
NF-kappa	O
B	O
activation	O
.	O

Our	O
data	O
suggest	O
that	O
[B]	O
lipoxygenase	protein
metabolites	protein
[E]	O
activate	O
ROI	O
formation	O
which	O
then	O
induce	O
IL-2	O
expression	O
via	O
NF-kappa	O
B	O
activation	O
.	O

Our	O
data	O
suggest	O
that	O
[B]	O
lipoxygenase	NEG
metabolites	NEG
activate	NEG
ROI	NEG
formation	NEG
which	NEG
then	NEG
induce	NEG
IL-2	NEG
[E]	O
expression	O
via	O
NF-kappa	O
B	O
activation	O
.	O

Our	O
data	O
suggest	O
that	O
[B]	O
lipoxygenase	NEG
metabolites	NEG
activate	NEG
ROI	NEG
formation	NEG
which	NEG
then	NEG
induce	NEG
IL-2	NEG
expression	NEG
via	NEG
NF-kappa	NEG
B	NEG
[E]	O
activation	O
.	O

Our	O
data	O
suggest	O
that	O
lipoxygenase	O
metabolites	O
activate	O
ROI	O
formation	O
which	O
then	O
induce	O
[B]	O
IL-2	protein
[E]	O
expression	O
via	O
NF-kappa	O
B	O
activation	O
.	O

Our	O
data	O
suggest	O
that	O
lipoxygenase	O
metabolites	O
activate	O
ROI	O
formation	O
which	O
then	O
induce	O
[B]	O
IL-2	NEG
expression	NEG
via	NEG
NF-kappa	NEG
B	NEG
[E]	O
activation	O
.	O

Our	O
data	O
suggest	O
that	O
lipoxygenase	O
metabolites	O
activate	O
ROI	O
formation	O
which	O
then	O
induce	O
IL-2	O
expression	O
via	O
[B]	O
NF-kappa	protein
B	protein
[E]	O
activation	O
.	O

Our	O
data	O
suggest	O
that	O
[B]	O
lipoxygenase	NEG
metabolites	NEG
activate	NEG
[E]	O
ROI	O
formation	O
which	O
then	O
induce	O
IL-2	O
expression	O
via	O
NF-kappa	O
B	O
activation	O
.	O

Our	O
data	O
[B]	O
suggest	NEG
that	NEG
lipoxygenase	NEG
[E]	O
metabolites	O
activate	O
ROI	O
formation	O
which	O
then	O
induce	O
IL-2	O
expression	O
via	O
NF-kappa	O
B	O
activation	O
.	O

Our	O
data	O
suggest	O
[B]	O
that	NEG
lipoxygenase	NEG
[E]	O
metabolites	O
activate	O
ROI	O
formation	O
which	O
then	O
induce	O
IL-2	O
expression	O
via	O
NF-kappa	O
B	O
activation	O
.	O

Our	O
data	O
suggest	O
[B]	O
that	NEG
lipoxygenase	NEG
metabolites	NEG
[E]	O
activate	O
ROI	O
formation	O
which	O
then	O
induce	O
IL-2	O
expression	O
via	O
NF-kappa	O
B	O
activation	O
.	O

Our	O
data	O
suggest	O
that	O
lipoxygenase	O
[B]	O
metabolites	NEG
[E]	O
activate	O
ROI	O
formation	O
which	O
then	O
induce	O
IL-2	O
expression	O
via	O
NF-kappa	O
B	O
activation	O
.	O

Our	O
data	O
suggest	O
that	O
lipoxygenase	O
metabolites	O
activate	O
ROI	O
formation	O
which	O
then	O
induce	O
[B]	O
IL-2	NEG
expression	NEG
[E]	O
via	O
NF-kappa	O
B	O
activation	O
.	O

Our	O
data	O
suggest	O
that	O
lipoxygenase	O
metabolites	O
activate	O
ROI	O
formation	O
which	O
then	O
induce	O
[B]	O
IL-2	NEG
expression	NEG
via	NEG
[E]	O
NF-kappa	O
B	O
activation	O
.	O

Our	O
data	O
suggest	O
that	O
lipoxygenase	O
metabolites	O
activate	O
ROI	O
formation	O
which	O
[B]	O
then	NEG
induce	NEG
IL-2	NEG
[E]	O
expression	O
via	O
NF-kappa	O
B	O
activation	O
.	O

Our	O
data	O
suggest	O
that	O
lipoxygenase	O
metabolites	O
activate	O
ROI	O
formation	O
which	O
then	O
[B]	O
induce	NEG
IL-2	NEG
[E]	O
expression	O
via	O
NF-kappa	O
B	O
activation	O
.	O

Our	O
data	O
suggest	O
that	O
lipoxygenase	O
metabolites	O
activate	O
ROI	O
formation	O
which	O
then	O
induce	O
IL-2	O
expression	O
via	O
[B]	O
NF-kappa	NEG
[E]	O
B	O
activation	O
.	O

Our	O
data	O
suggest	O
that	O
lipoxygenase	O
metabolites	O
activate	O
ROI	O
formation	O
which	O
then	O
induce	O
IL-2	O
expression	O
via	O
[B]	O
NF-kappa	NEG
B	NEG
activation	NEG
[E]	O
.	O

Our	O
data	O
suggest	O
that	O
lipoxygenase	O
metabolites	O
activate	O
ROI	O
formation	O
which	O
then	O
induce	O
IL-2	O
expression	O
[B]	O
via	NEG
NF-kappa	NEG
B	NEG
[E]	O
activation	O
.	O

Our	O
data	O
suggest	O
that	O
lipoxygenase	O
metabolites	O
activate	O
ROI	O
formation	O
which	O
then	O
induce	O
IL-2	O
expression	O
via	O
NF-kappa	O
[B]	O
B	NEG
[E]	O
activation	O
.	O

HIV-1	O
and	O
HIV-2	O
display	O
significant	O
differences	O
in	O
[B]	O
nucleic	DNA
acid	DNA
sequence	DNA
[E]	O
and	O
in	O
the	O
natural	O
history	O
of	O
clinical	O
disease.	O

HIV-1	O
and	O
HIV-2	O
display	O
significant	O
differences	O
in	O
[B]	O
nucleic	NEG
[E]	O
acid	O
sequence	O
and	O
in	O
the	O
natural	O
history	O
of	O
clinical	O
disease.	O

HIV-1	O
and	O
HIV-2	O
display	O
significant	O
differences	O
in	O
[B]	O
nucleic	NEG
acid	NEG
[E]	O
sequence	O
and	O
in	O
the	O
natural	O
history	O
of	O
clinical	O
disease.	O

HIV-1	O
and	O
HIV-2	O
display	O
significant	O
differences	O
in	O
nucleic	O
[B]	O
acid	NEG
sequence	NEG
[E]	O
and	O
in	O
the	O
natural	O
history	O
of	O
clinical	O
disease.	O

HIV-1	O
and	O
HIV-2	O
display	O
significant	O
differences	O
in	O
nucleic	O
acid	O
[B]	O
sequence	NEG
[E]	O
and	O
in	O
the	O
natural	O
history	O
of	O
clinical	O
disease.	O

This	O
site	O
is	O
conserved	O
among	O
isolates	O
of	O
HIV-2	O
and	O
the	O
closely	O
related	O
simian	O
immunodeficiency	O
virus	O
,	O
and	O
transfection	O
assays	O
show	O
this	O
site	O
to	O
mediate	O
[B]	O
HIV-2	DNA
enhancer	DNA
[E]	O
activation	O
following	O
stimulation	O
of	O
monocytic	O
but	O
not	O
T-cell	O
lines	O
.	O

This	O
site	O
is	O
conserved	O
among	O
isolates	O
of	O
HIV-2	O
and	O
the	O
closely	O
related	O
simian	O
immunodeficiency	O
virus	O
,	O
and	O
transfection	O
assays	O
show	O
this	O
site	O
to	O
mediate	O
[B]	O
HIV-2	NEG
enhancer	NEG
activation	NEG
following	NEG
stimulation	NEG
of	NEG
monocytic	NEG
[E]	O
but	O
not	O
T-cell	O
lines	O
.	O
